Author:
Suda Kenichi,Mitsudomi Tetsuya
Funder
Grants-in-Aid of Cancer Research from the Ministry of Education, Science, Sports, and Culture of Japan
Grants from the Japan Surgical Society (JSS) Young Researcher Award 2014
The Kaibara Morikazu Medical Science Promotion Foundation
The Uehara Memorial Foundation
The Takeda Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology,General Medicine
Reference102 articles.
1. Arcila ME, Oxnard GR, Nafa K et al (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17(5):1169–1180
2. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932–20937
3. Ceppi P, Volante M, Novello S et al (2006a) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17(12):1818–1825
4. Ceppi P, Volante M, Saviozzi S et al (2006b) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7):1589–1596
5. Chen Z, Liu X, Zhao J, Yang H, Teng X (2014) Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol 7(11):8039–8045
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献